Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Susceptibility

In Vitro Activities of MCB3681 and Eight Comparators against Clostridium difficile Isolates with Known Ribotypes and Diverse Geographical Spread

Jane Freeman, Sally Pilling, Jonathan Vernon, Mark H. Wilcox
Jane Freeman
aMicrobiology, Leeds Teaching Hospitals Trust, University of Leeds, Leeds, United Kingdom
bHealthcare Associated Infections Research Group, Leeds Institute for Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sally Pilling
bHealthcare Associated Infections Research Group, Leeds Institute for Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Vernon
bHealthcare Associated Infections Research Group, Leeds Institute for Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark H. Wilcox
aMicrobiology, Leeds Teaching Hospitals Trust, University of Leeds, Leeds, United Kingdom
bHealthcare Associated Infections Research Group, Leeds Institute for Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.02077-16
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Treatments for Clostridium difficile infection remain limited, despite the introduction of fidaxomicin, and development of new agents is necessary. We determined the in vitro susceptibilities of 199 prevalent or emerging Clostridium difficile PCR ribotypes to MCB3681, a novel investigational quinolonyl-oxazolidinone, and 8 comparators (metronidazole, vancomycin, fidaxomicin, moxifloxacin, ciprofloxacin, clindamycin, tigecycline, and linezolid). MCB3681 showed good activity against C. difficile with no evidence of MCB3681 resistance in isolates showing either moxifloxacin or linezolid resistance or both moxifloxacin and linezolid resistance.

TEXT

Clostridium difficile infection (CDI) is a major burden on health care resources. CDI is thought to arise following the depletion of gut microflora by antimicrobial action, allowing the organism to proliferate and cause disease. Antimicrobial treatments for CDI are currently limited to metronidazole, vancomycin, and fidaxomicin. Metronidazole has more recently been associated with treatment failures, while promotion of glycopeptide resistance within the host microflora is a risk associated with vancomycin therapy (1). Symptomatic recurrence is common following treatment with these agents (2), requiring further episodes of antimicrobial therapy. Further treatment options are highly desirable to broaden the range of therapeutic choice and strengthen antimicrobial stewardship.

MCB3681 is a novel small molecule with structural elements of an oxazolidinone and a quinolone showing good activity against C. difficile, including isolates that were resistant to linezolid, ciprofloxacin, moxifloxacin, and clindamycin (3). It achieves high fecal concentrations after intravenous infusions and has shown activity against Gram-positive components of the gut microflora in a clinical phase 1 study (4). The development of an intravenous treatment agent achieving high fecal concentrations would circumvent issues of rapid gut transit or of impaired delivery of orally administered agents due to ileus, particularly in patients with severe or protracted/multiple recurrent diarrheal episodes.

We determined the in vitro activities of MCB3681 and 8 comparators (metronidazole, vancomycin, moxifloxacin, ciprofloxacin, clindamycin, tigecycline, linezolid, and fidaxomicin) against a panel of 200 Clostridium difficile isolates of known PCR ribotypes (RTs) from 21 European countries (selected from the ClosER study, July 2011 to April 2013, by kind permission of Astellas Pharma Europe) (5).

In vitro susceptibility testing was performed using a Wilkins-Chalgren agar incorporation method, as previously described (5, 6). Briefly, C. difficile test isolates and control strains (C. difficile ATCC 750057, C. difficile E4 PCR ribotype 010, Bacteroides fragilis ATCC 25285, Enterococcus faecalis ATCC 29212, and Staphlyococcus aureus ATCC 29213) were cultured anaerobically at 37°C for 24 h in Schaedler anaerobic broth prior to dilution to a 0.5 McFarland standard equivalence in prereduced sterile saline solution and inoculation onto antibiotic-containing and control Wilkins-Chalgren agar plates. Inoculated plates were incubated anaerobically at 37°C for 48 h.

MCB3681 is a quinolonyl-oxazolidinone antibacterial which has previously demonstrated good activity against C. difficile (3). All the CDI treatment agents, including MCB3681, showed good activity against the isolates tested (Table 1). Fidaxomicin was the most active treatment agent (Kruskal-Wallis P = <0.0001; geometric mean [GM] MIC = 0.05 mg/liter), followed by MCB3681 (P = <0.0001; GM MIC = 0.12 mg/liter) and then metronidazole (P = <0.0001; GM MIC = 0.33 mg/liter), with no evidence of resistance to any of these compounds (Table 1). Vancomycin was the least active (P = <0.0001; GM MIC = 1.02 mg/liter), but resistance was very scarce (1.5%; breakpoint = >8 mg/liter). Reduced metronidazole susceptibility (MIC = 4 mg/liter) was observed in only 1% of isolates. GM metronidazole MICs were elevated in RT027 (0.96 mg/liter) and RT106 (0.74 mg/liter) versus the GM metronidazole MIC for all isolates tested (0.33 mg/liter), in agreement with previous data (4).

View this table:
  • View inline
  • View popup
TABLE 1

Susceptibility of 199 C. difficile isolates to MCB3681 and 8 comparatorsa

All isolates were resistant to ciprofloxacin according to the defined breakpoints (Table 1), and 48% of isolates, including at least one isolate in each RT group tested, showed moxifloxacin resistance. Highly elevated MICs of both moxifloxacin (≥32 mg/liter) and ciprofloxacin (≥128 mg/liter) were prevalent for RT001, RT027, and RT356. Clindamycin MICs were highest for RT001, RT017, and RT126 (GM MICs = 61.11 mg/liter; 64 mg/liter, and 38.05 mg/liter, respectively), but there was evidence of clindamycin resistance in all RTs tested (Table 1). There was no evidence of tigecycline resistance (range = 0.03 to 0.125 mg/liter; GM MIC = 0.05 mg/liter), in agreement with previous data (4) (Table 1). The majority of isolates (78.9%) were sensitive to linezolid (table 1), with a GM MIC of 5.16 mg/liter. RT001 and RT017 showed the highest GM linezolid MICs (10.08 mg/liter and 7.03 mg/liter, respectively). This also is in agreement with previous observations (6). Three RT017 isolates and two RT027 isolates showed dual quinolone-oxazolidinone resistance phenotypes and MCB3681 MICs of 0.5 mg/liter. We have previously reported that these isolates showed high-level resistance to chloramphenicol (Table 2) (5, 7). Marín et al. reported linezolid, chloramphenicol, erythromycin, and clindamycin resistance associated with the presence of the multidrug resistance gene cfr in C. difficile RT017, RT078, and RT126 isolates (8).

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 2

MCB3681 MICs in C. difficile isolates with dual quinolone-oxazolidinone resistancea

The MIC50 and MIC90 values reported here for MCB3681 are similar to those recently described for cadazolid, another quinolonyl-oxazolidinone molecule (9). A previous study investigating the susceptibility of C. difficile to cadazolid and comparators reported an association between resistance to either moxifloxacin or linezolid and moxifloxacin/linezolid doubly resistant mutants and 2- or 4-fold-higher cadazolid MICs in mono- or doubly resistant isolates, respectively (10). However, the highest MCB3681 MIC was 0.5 mg/liter, and we also found isolates with moxifloxacin, ciprofloxacin, linezolid, and chloramphenicol resistance that demonstrated very low MCB3681 MICs (0.008 mg/liter) (Table 2). We did not investigate the molecular basis of resistance in these isolates, but the results do not suggest a link between this phenotype and MCB3681 MICs. The results shown here, in conjunction with those previously reported (7, 8), would also seem to indicate that other modes of resistance to linezolid (23S rRNA alterations, ribosomal protein modifications) may be at play in combination with quinolone resistance mechanisms.

Rashid et al. reported that MICs of MCB3681 for C. difficile ranged from 0.008 to 0.5 mg/liter (3), which were values similar to our results (range, 0.008 to 0.5 mg/liter). However, in the present study, MIC50 and MIC90 values were 0.125 and 0.25 mg/liter, respectively, which were marginally higher than those reported previously but were within 2 doubling dilutions (0.03 and 0.06 mg/liter, respectively). This may be explained by methodology/agar or C. difficile strain distribution differences. The influence of testing media and components therein on MICs has previously been reported and may have been a factor in the differences observed (6, 11). We used a Wilkins-Chalgren agar incorporation method to determine MICs, since that method is superior to the use of CLSI-recommended brucella blood agar (BBA) in the detection of reduced susceptibility to metronidazole in C. difficile (6).

This report builds on the data previously reported by Rashid et al. by substantially expanding the diversity of ribotypes examined to include, in particular, RT027 and several RTs already noted for resistance to multiple antimicrobials: RT001, RT017, RT018, RT027, and RT356 (5, 7). There was no evidence of MCB3681 resistance among them. MCB3681 achieves fecal concentrations of 99 to 226 mg/kg of body weight after intravenous infusions, far in excess of the MIC ranges for C. difficile reported here. MCB3681 has been reported to be active against Gram-positive gut microflora bacteria but to be sparing of Gram-negative organisms in human volunteer studies with intravenous administration over 5 days. Further data are needed to assess the impact of MCB3681 on C. difficile and the gut microflora over a longer duration.

In summary, MCB3681 showed good activity against C. difficile isolates from emerging or prevalent European PCR ribotypes with no evidence of resistance. The presence of quinolone and/or linezolid resistance did not influence MCB3681 MICs.

ACKNOWLEDGMENTS

We are grateful to Chris Longshaw and Astellas Pharma Europe for kind permission to use C. difficile isolates collected during The ClosER study.

This research was funded by Morphochem AG, Munich, Germany. J.F. has grant/research funding outside this work from Astellas and Melinta Therapeutics; M.H.W. has received grant/research funding outside this work from Abbott, Actelion, Alere, Astellas, bioMérieux, Cerexa, Cubist, Da Volterra, European Tissue Symposium, Merck, Sanofi-Pasteur, Summit, The Medicines Company, and Qiagen and consultancies and/or lecture honoraria from Actelion, Alere, Astellas, Astra-Zeneca, Basilea, Bayer, Cubist, Durata, European Tissue Symposium, J&J, Merck, Nabriva, Novacta, Novartis, Optimer, Pfizer, Roche, Sanofi-Pasteur, and Seres and has been a member of a speaker's bureau for Pfizer.

J.V. and S.P. have no potential conflicts of interest to declare.

FOOTNOTES

    • Received 27 September 2016.
    • Returned for modification 7 November 2016.
    • Accepted 3 December 2016.
    • Accepted manuscript posted online 19 December 2016.
  • Copyright © 2017 Freeman et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license .

REFERENCES

  1. 1.↵
    1. Al-Nassir WN,
    2. Sethi AK,
    3. Li Y,
    4. Peltz MJ,
    5. Riggs MM,
    6. Sonskey CJ
    . 2008. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother52:2403–2406. doi:10.1128/AAC.00090-08.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Debast SB,
    2. Bauer MP,
    3. Kuijper EJ
    ; European Society of Clinical Microbiology and Infectious Diseases. 2014. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect20(Suppl 2):1–26. doi:10.1111/1469-0691.12418.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Rashid M-U,
    2. Dalhoff A,
    3. Weintraub A,
    4. Nord CE
    . 2014. In vitro activity of MCB3681 against Clostridium difficile strains. Anaerobe28:216–219. doi:10.1016/j.anaerobe.2014.07.001.
    OpenUrlCrossRef
  4. 4.↵
    1. Dalhoff A,
    2. Rashid M-U,
    3. Kapsner T,
    4. Panagiotidis G,
    5. Weintraub A,
    6. Nord CE
    . 2015. Analysis of effects of MCB3681, the antibacterially active substance of prodrug MCB3867, on human resident microflora as proof of principle. Clin Microbiol Infect21:767.e1–767.e4. doi:10.1016/j.cmi.2015.05.025.
    OpenUrlCrossRef
  5. 5.↵
    1. Freeman J,
    2. Vernon J,
    3. Morris K,
    4. Nicholson S,
    5. Todhunter S,
    6. Lonshaw C,
    7. Wilcox MH
    ; Pan-European Longitudinal Surveillance of Antibiotic Resistance among Prevalent Clostridium difficile Ribotypes' Study Group. 2015. Pan-European longitudinal surveillance of antimicrobial resistance among prevalent Clostridium difficile ribotypes. Clin Microbiol Infect21:248.e9–248.e16. doi:10.1016/j.cmi.2014.09.017.
    OpenUrlCrossRef
  6. 6.↵
    1. Baines SD,
    2. O'Connor R,
    3. Freeman J,
    4. Fawley WN,
    5. Harmanus C,
    6. Mastrantonio P,
    7. Kuijper EJ,
    8. Wilcox MH
    . 2008. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother62:1046–1052. doi:10.1093/jac/dkn313.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Freeman J,
    2. Vernon JJ,
    3. Vickers R,
    4. Wilcox MH
    . 2015. Susceptibility of Clostridium difficile isolates of varying antimicrobial resistance phenotypes to SMT19969 and 11 comparators. Antimicrob Agents Chemother60:689–692. doi:10.1128/AAC.02000-15.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Marín M,
    2. Martín A,
    3. Alcalá L,
    4. Cercenado E,
    5. Iglesias C,
    6. Reigadas E,
    7. Bouza E
    . 2015. Clostridium difficile isolates with high linezolid MICs harbor the multiresistance gene cfr. Antimicrob Agents Chemother59:586–589. doi:10.1128/AAC.04082-14.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Gerding DN,
    2. Hecht DW,
    3. Louie T,
    4. Nord CE,
    5. Talbot GH,
    6. Cornely OA,
    7. Buitrago M,
    8. Best E,
    9. Sambol S,
    10. Osmolski JR,
    11. Kracker H,
    12. Locher HH,
    13. Charef P,
    14. Wilcox M
    . 2016. Susceptibility of Clostridium difficile isolates from a phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection. J Antimicrob Chemother71:213–219. doi:10.1093/jac/dkv300.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Locher HH,
    2. Seiler P,
    3. Chen X,
    4. Schroeder S,
    5. Pfaff P,
    6. Enderlin M,
    7. Lkenk A,
    8. Fournier E,
    9. Hubschwerlen C,
    10. Ritz D,
    11. Kelly CP,
    12. Keck W
    . 2014. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infection. Antimicrob Agents Chemother58:892–900. doi:10.1128/AAC.01830-13.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Wu X,
    2. Hurdle JG
    . 2015. Hemin modulates metronidazole susceptibility of Clostridium difficile, abstr C-576. Abstr 55th Intersci Conf Antimicrob Agents Chemother,San Diego, CA.
PreviousNext
Back to top
Download PDF
Citation Tools
In Vitro Activities of MCB3681 and Eight Comparators against Clostridium difficile Isolates with Known Ribotypes and Diverse Geographical Spread
Jane Freeman, Sally Pilling, Jonathan Vernon, Mark H. Wilcox
Antimicrobial Agents and Chemotherapy Feb 2017, 61 (3) e02077-16; DOI: 10.1128/AAC.02077-16

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Vitro Activities of MCB3681 and Eight Comparators against Clostridium difficile Isolates with Known Ribotypes and Diverse Geographical Spread
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
In Vitro Activities of MCB3681 and Eight Comparators against Clostridium difficile Isolates with Known Ribotypes and Diverse Geographical Spread
Jane Freeman, Sally Pilling, Jonathan Vernon, Mark H. Wilcox
Antimicrobial Agents and Chemotherapy Feb 2017, 61 (3) e02077-16; DOI: 10.1128/AAC.02077-16
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Anti-Bacterial Agents
Clostridium difficile
oxazolidinones
quinolones
Clostridium difficile
MCB3681
antimicrobial susceptibility

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596